Marker Therapeutics is trading 5.89% lower at $0.95, in line with biotech-sector weakness; no company-specific catalyst was identified.
- No new company-specific announcement was identified for October 13; the investor-relations page lists a September 22 press release as its latest release.
- XBI was down 2.01% during the regular session; major indexes were only slightly lower.
- Volume and other trading-activity details were not provided.